In July, US Surgeon General Dr. Vivek Murthy issued a landmark advisory declaring firearm violence a national public health crisis. The advisory builds on decades of work from Dr. Megan Ranney and other researchers who advocate taking a public health approach to reducing firearm violence. She joined us at Aspen Ideas: Health to discuss what this means: namely moving from a focus on law and order to centering harm reduction and prevention. Now, as the Dean of the Yale School of Public Health, Megan is applying the same systems thinking approach to focus on the big changes we need to drive health in the US.

We discuss:

• What it means to be a great public health communicator
• How public health approaches were used to dramatically reduce automobile deaths over the last 50 years, and how the same strategies should be used now to tackle firearm deaths
• Her take on bridging the gap between medical care and public health

Megan says this is the moment for public health reinvention:

“This is a moment where we get to reinvent how we study, teach, and most of all, practice public health, not just locally, but also globally, as we come out of the COVID pandemic, and I think there's a real moral clarity, but also a moral imperative for us, as public health professionals, to seize this moment, to take this kind of pivot point that we're at as a field, and to move it forward in a direction that we will be proud of.”

Relevant Links

Megan Ranney testimony on gun violence as a public health issue

Gun violence panel at Aspen Ideas: Health

Surgeon General advisory on firearm violence

Yale Q&A with Dean Megan Ranney

Common health coalition

Bipartisan Safer Communities Act

UC Berkeley School of Public Health course on urban gun violence prevention

More on Rahimi case

About Our Guest

Dr. Megan L. Ranney is an emergency physician, researcher, and national advocate for innovative approaches to public health. In July 2023, she joined Yale University as Dean of the Yale School of Public Health, where she is also the C.-E. A. Winslow Professor of Public Health. Her research focuses on developing, testing, and disseminating digital health interventions to prevent violence and related behavioral health problems, and on COVID-related risk reduction. She has held multiple national leadership roles, including as co-founder of...

Deena Shakir is an investor who is obsessed with expanding access to the basic health services people need and often can’t access: pediatric care, community health and women’s services. Her journey to investing passed through policymaking, journalism and big tech and her early techno optimism has given way to a much more nuanced and pragmatic view. She is able to see the big opportunities for impact hiding in plain sight.

We discuss:

• The two obvious megatrends hitting healthcare: GLP1s and AI
• And the not so obvious opportunity: doing basic things better
• How Dobbs was an accelerant, not a deterrent, for investments in women’s health
• Why Public Health is great training for healthcare founders

Deena is excited about “asset light” investments that combine new care models – like community health workers – and technology:

“There are some things that won't change. And there are things that hopefully tech can help to navigate. And so these asset light models, these models that are leveraging under leveraged care workers – like community health workers that are providing culturally competent care – and at the end of the day, that are improving metrics and outcomes, are the ones that get me excited.”

Relevant Links

Lux Capital

Jonathan Haidt article in The Atlantic titled “Why the past 10 years of American Life have been uniquely stupid”

President Obama’s Cairo speech

ARPA-H Sprint for Women’s Health

Health companies Deena mentions that she invests in:

Waymark

Summer health

Maven Clinic

About Our Guest

Deena's investments span stages and sectors, and include women's health, digital health infrastructure, health equity, foodtech, and fintech. Above all, she seeks out extraordinary, often underdog, founders on a mission. Prior to Lux, Deena was a Partner at GV (formerly Google Ventures), led product partnerships at Google for health, search, and AI/ML, and directed social impact investments at Google.org. Deena also served as a Presidential Management Fellow at The U.S. Department of State under Secretary Clinton, where she helped launch President Obama’s first Global Entrepreneurship...

Government systems often take a lot of flack for their (sometimes) built-in inability to take risks and make big bets. So, what would it take to encourage the government to take those big, risky moonshots? For Health, that’s the role of ARPA-H – to fund new ways of improving health by investing in people with big ideas. We sat down with ARPA-H Director Renee Wegrzyn at Aspen Ideas Health to talk about how it’s going and what comes next.

We discuss:

• Why ARPA-H is personal for President Biden.
• How ARPA-H’s special authorities – from flexible hiring to novel contracting – are its secret weapons for speed and scale.
• The critical role of Program Managers – single decision maker driving the vision and execution of each $50-$200 million initiative.

Renee says ARPA-H gives her the ability to direct funds into areas that are sometimes left off the list of “must haves” for innovation:

“...one of the only top down things I've done as a director is said, ‘Why aren't we funding more in women's health? We don't have any program managers in the pipeline that want to exclusively focus on this’. But I think we all inherently understand that women are underrepresented in almost every aspect of health. So I asked our [Program Managers].. who wants to raise [a] hand and pick a topic that is really either unique to women, or is disproportionately affecting women that we can do a sprint and invest around. And so I got six Program Managers to come up with topics, everything from Women's Health at home, to brain health, to understanding and quantifying pain – and through the Investor Catalyst Hub we have worked with investors to understand what kind of convincing scale do we need to get to for you to be the second investor. And we competed this across the country.”

Relevant Links

• About ARPA-H
• ARPA-H Health Equity Factsheet
• The Minor Consult Podcast Episode
• ARPA - H Timeline
• Youtube Conversation with New Yorker writer
• White House FAQ Sheet on ARPA-H

About Our Guest

Dr. Renee Wegrzyn is the first director of the Advanced Research Projects Agency for Health (ARPA-H), appointed by President Biden on October 11, 2022. Previously, she was the Vice President of Business Development at Ginkgo Bioworks and Head of Innovation at Concentric by Ginkgo, where she focused on synthetic biology for combating infectious diseases like COVID-19.

Wegrzyn has experience with DARPA and IARPA, the models for ARPA-H. At DARPA, she used synthetic biology and gene editing to enhance biosecurity and the bioeconomy, managing programs like Living Foundries, Safe Genes, PREPARE, and DIGET. She received the Superior Public Service Medal for her DARPA work. Her career includes leading biosecurity and gene therapy teams in private industry, developing immunoassays and diagnostics. Wegrzyn has served on various scientific advisory boards, including those for the National Academies and the Air Force Research Labs. She holds a Ph.D. and a bachelor's degree in applied biology from the Georgia Institute of Technology and completed...